Enveric Biosciences Reports New Brain Activity Data for Psychedelic-Derived Drug Candidate
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT ...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT ...
US biotechnology company Enveric Biosciences has reported encouraging laboratory results for EB-003, an experimental psychiatric medicine designed to promote neuroplasticity ...
The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
